L-dopa level in plasma, primary condition for the kinetic effect.
D000284:Administration, Oral; D000368:Aged; D000547:Amantadine / Q000008:administration & dosage / Q000627:therapeutic use; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001702:Biopharmaceutics; D001921:Brain / Q000378:metabolism; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000097:blood* / Q000378:metabolism / Q000627:therapeutic use; D004357:Drug Synergism; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D006834:Hydrazines; D004295:Dihydroxyphenylalanine; D000547:Amantadine